Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma.
Liposome, albumin and polymer polyethylene glycol are nanovector formulations successfully developed for anti-cancer drug delivery. There are significant differences in pharmacokinetics, efficacy and toxicity between pre- and post-nanovector modification. The alteration in clinical pharmacology is instrumental for the future development of nanovector-based anticancer therapeutics. We have reviewed the results of clinical studies and translational research in nanovector-based anti-cancer therapeutics in advanced pancreatic adenocarcinoma, including nanoparticle albumin-bound paclitaxel and nanoliposomal irinotecan. Furthermore, we have appraised the ongoing studies incorporating novel agents with nanomedicines in the treatment of pancreatic adenocarcinoma.
Chung-Tzu Hsueh, Department of Dentistry, Cathay General Hospital, Taipei 10630, Taiwan.
Chung-Tzu
CT
Hsueh
Chung-Tzu Hsueh, Department of Dentistry, Cathay General Hospital, Taipei 10630, Taiwan.
Julie H
JH
Selim
Chung-Tzu Hsueh, Department of Dentistry, Cathay General Hospital, Taipei 10630, Taiwan.
James Y
JY
Tsai
Chung-Tzu Hsueh, Department of Dentistry, Cathay General Hospital, Taipei 10630, Taiwan.
Chung-Tsen
CT
Hsueh
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018395:CA-19-9 Antigen / Q000097:blood; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D016503:Drug Delivery Systems; D006801:Humans; D000077146:Irinotecan; D008081:Liposomes; D053758:Nanoparticles; D017239:Paclitaxel / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality
D000970:Antineoplastic Agents; D018395:CA-19-9 Antigen; D008081:Liposomes; D000077146:Irinotecan; D017239:Paclitaxel; D002166:Camptothecin
Biomarker; Nanoliposomal irinotecan; Nanoparticle albumin-bound paclitaxel; Nanovector; Pancreatic adenocarcinoma